基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights 2022-06-01 00:35
CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis 2022-05-17 08:02
CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022 2022-04-28 08:00
CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine 2022-04-22 08:02
CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American Association for Cancer Research (AACR) Annual Meeting 2022 2022-04-13 08:02
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC 2022-03-31 08:02
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China 2022-03-18 10:35
CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target 2022-03-18 08:37
CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer 2022-03-14 08:05
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China 2022-02-17 09:19
CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia 2022-02-09 11:53
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients 2022-01-19 08:05
CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment 2022-01-18 08:00
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology 2022-01-15 08:35
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology 2022-01-15 08:31
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) 2022-01-13 08:05
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration 2022-01-03 08:00
CStone announced new drug approval of precision therapy AYVAKIT® (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST) 2021-12-28 08:00
CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER 2021-12-21 16:56
Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia 2021-12-12 09:00
1 2 3 4 5 7